OCUL OCULAR THERAPEUTIX, INC

Nasdaq ocutx.com


$ 11.84 $ -0.36 (-2.95 %)    

Friday, 17-Oct-2025 15:59:56 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 11.84
$ 11.94
$ 11.45 x 1
$ 12.11 x 1
$ 11.48 - $ 12.16
$ 5.79 - $ 13.85
3,399,099
na
2.06B
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 03-10-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-ocular-therapeutix-raises-price-target-to-19

HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target fr...

 piper-sandler-maintains-overweight-on-ocular-therapeutix-raises-price-target-to-31

Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and raises the price target fr...

 baird-maintains-outperform-on-ocular-therapeutix-raises-price-target-to-24

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $17...

 chardan-capital-maintains-buy-on-ocular-therapeutix-maintains-21-price-target

Chardan Capital analyst Daniil Gataulin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.

 needham-maintains-buy-on-ocular-therapeutix-raises-price-target-to-20

Needham analyst Serge Belanger maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $15 to...

 jmp-securities-maintains-market-outperform-on-ocular-therapeutix-raises-price-target-to-29

JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the ...

 ocular-therapeutix-raises-475m-in-stock-offering-of-379m-shares-at-1253share-to-fund-eye-disease-drug-trials

Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular", the "Company"), an integrated biopharmaceutical company commi...

 ocular-therapeutix-showcases-progress-on-new-eye-drug-that-could-change-treatment-for-vision-loss

Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the...

 chardan-capital-initiates-coverage-on-ocular-therapeutix-with-buy-rating-announces-price-target-of-21

Chardan Capital analyst Daniil Gataulin initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announc...

 scotiabank-maintains-sector-outperform-on-ocular-therapeutix-lowers-price-target-to-20

Scotiabank analyst Greg Harrison maintains Ocular Therapeutix (NASDAQ:OCUL) with a Sector Outperform and lowers the price ta...

 ocular-therapeutix-q2-eps-039-misses-036-estimate-sales-13459m-beat-13253m-estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION